Intellia Therapeutics, Inc. — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Intellia Therapeutics, Inc. (NTLA)
CIK: 0001652130
Period of Report: 2025-03-01

Reporting Person: Schultes Birgit C (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-01	Common Stock	A	37600	—	Acquired	105215	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-01	Stock Option (right to buy)	$10.09	A	53714	Acquired	2035-02-28	Common Stock (53714)	Direct

Footnotes

F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

F2: This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.